BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) for BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues pertaining to access to quality care for blood cancer patients [HR 460, Patients Access to Treatments Act - all provisions]; [HR 1801, The Cancer Drug Coverage Parity Act - all provisions]; [HR 2827, The Part D Beneficiary Appeals Fairness Act - all provisions]; [P.L. 111-148, the Patient Protection and Affordable Care Act - provisions specific to Medicaid and end of life issues]
| Lobbyist | Covered position, as disclosed |
|---|---|
| DIANA CHRISTIAN | — |
| EMILY SHETTY | Legislative Director, Rep. Edolphus Towns |
Budget/Appropriations BUD
Issues pertaining to the FDA drug approval process and agency funding - [HR 2725, the FDA Safety Over Sequestration Act]; Issues pertaining to funding for the National Center for the Advancement of Translational Sciences and the National Institutes of Health, specifically for pediatric and general cancer research - [FY14 Labor Health and Human Services and Related Agencies subcommittee bill - provisions related to NCATS & NIH]
| Lobbyist | Covered position, as disclosed |
|---|---|
| DIANA CHRISTIAN | — |
| EMILY SHETTY | Legislative Director, Rep. Edolphus Towns |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.